Methods of treating proliferative diseases
AssigneeAmbit Biosciences Corporation
InventorsRobert E. Corringham, Patrick B. O'Donnell, Joyce K. James
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
Claims60
A method of treating a proliferative disease in a patient, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of the compound of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof, wherein the therapeutically effective amount is at least about 12 mg per day, and wherein the compound is administered on an empty stomach.
A method of treating a proliferative disease in a mammal, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of the compound of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof, wherein the therapeutically effective amount is about 150 mg per day.
A spray-dried pharmaceutical composition comprising a compound of Formula I,
- or a pharmaceutically acceptable salt or solvate thereof, and hydroxypropyl-β-cyclodextrin.
Dependencies are inferred from the claim text.